ESCRS - PO409 - Comparative Evaluation Of Visual Performance With A Miol And A Novel Spiral Full Range Of Vision Iol: A Retrospective Analysis

Comparative Evaluation Of Visual Performance With A Miol And A Novel Spiral Full Range Of Vision Iol: A Retrospective Analysis

Published 2025 - 43rd Congress of the ESCRS

Reference: PO409 | Type: Free paper | DOI: 10.82333/cp1a-na42

Authors: Mayank Nanavaty* 1 , Ritika Mukhija 1 , Zahra Ashena 1 , Catey Bunce 2 , David Spalton 3

1University Hospitals Sussex NHS Foundation Trust,Brighton,United Kingdom, 2Royal Marsden,London,United Kingdom, 3Kings College ,London,United Kingdom

Purpose

Evaluation of Visual Acuity and Defocus Curve in pseudophakic patients having bilateral surgery with a Panoptix Trifocal IOL and a brand new Spiral IOL (Galaxy).

Setting

Multiple-site retrospective analysis – IRCCS Policlinico San Donato Hospital, Milan Italy; Fatebenefratelli e Oftalmico Hospital, Milan Italy

Methods

20 Patients (40 eyes) had bilateral bilateral cataract surgery with implantation of novel spiral full range of vision IOL( Rayner RayOne Galaxy) . Preoperatively and postoperatively at 4 months visual outcomes were assessed. Postoperative examinations included assessing distance, intermediate and near visual acuity (ETDRS charts) and binocular defocus. Data were compared with those of a previous publication of the author with a Trifocal IOL (Alcon Panoptix).

Results

Four months after the second eye surgery,  the DCNVA was similar for both of the MIOLs. However, a trend towards improved intermediate visual performance was observed for the Galaxy, as well as evaluating the defocus curve under photopic circumstances. No difference were found in UDVA and CDVA. Binocular CDVA: -0.01 ± 0.01 logMAR (Panoptix); 0.01 ± 0.01 logMAR (Galaxy); Binocular DCNVA: 0.01± 0.04 logMAR (Panoptix); 0.02 ± 0.01 logMAR (Galaxy); Binocular DCIVA: 0.13 ± 0.07 LOGmar (Panoptix); 0.02 ± 0.08 logMAR (Galaxy). 

Conclusions

Both MIOLs seemed to be good options for patients with near-vision requirements; however these results suggest that the novel spiral IOL offers a promising alternative for patients seeking premium IOL options with high levels of spectacle independence. Could be worthy comparing visual side effects and quality of vision of Alcon Panoptix with this novel spiral design.